https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44025 1), Compritol® 888 ATO (X₂) and equal ratio of poloxamer 188: sodium taurocholate (% w/w) (X₃) on particle size, zeta potential and entrapment efficiency. The optimised formulation (SLN₈) was found to be spherical in shape with mean particle size 187.9 ± 10.73 nm and zeta potential −47.4 mV. The maximum percentage entrapment of RIF, INH and PYZ in the optimised formulation was found to be 86.40 ± 0.274, 83.84 ± 0.269 and 81.43 ± 0.576, respectively. The in-vitro drug release study demonstrated that the release of drug from SLNs was slow in comparison to marketed formulation and pure ATDs. Cytotoxicity of the ATDs-SLNs was studied on murine macrophage cell line (RAW 264.7) using modified MTT assay demonstrated two folds growth inhibition of M. marinum as compared to standard antitubercular drugs. Overall, the developed SLNs may be considered as a promising anti-mycobacterial nano-drug, providing a new direction to the tuberculosis clinics.]]> Wed 05 Oct 2022 15:25:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23362 Sat 24 Mar 2018 07:16:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22700 a) with the effect of CVVHDF modeled as a time-dependent covariate. This suggested that there was initially good clearance with CVVHDF (4 times endogenous clearance), which rapidly declined within hours.]]> Sat 24 Mar 2018 07:15:25 AEDT ]]>